Trial intelligence / Profile preview

Apatinib mesylate combined with temozolomide for recurrent high-grade glioma

ChiCTR-OPC-16010108Phase 4Recruiting

Sponsor
First Affiliated Hospital of Soochow University
Start
Nov 2016
Modality
Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 4, open-label, single-arm trial of latanoprost and temozolomide in glioma, sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: progression free survival. Started Nov 2016; status: recruiting.

02

Drugs

latanoprosttemozolomide
03

Conditions

glioma

Beyond the preview

Go deeper on ChiCTR-OPC-16010108.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR-OPC-16010108.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call